Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2002 1
2003 1
2005 1
2006 1
2007 1
2008 2
2009 2
2010 3
2011 5
2012 3
2013 6
2014 3
2015 9
2016 12
2017 12
2018 25
2019 23
2020 15
2021 24
2022 32
2023 35
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN. Wang H, et al. JAMA Surg. 2021 May 1;156(5):444-451. doi: 10.1001/jamasurg.2021.0133. JAMA Surg. 2021. PMID: 33729467 Free PMC article. Clinical Trial.
Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J. Yang H, et al. JAMA Surg. 2021 Aug 1;156(8):721-729. doi: 10.1001/jamasurg.2021.2373. JAMA Surg. 2021. PMID: 34160577 Free PMC article. Clinical Trial.
IMPORTANCE: The prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains poor after surgery. ...
IMPORTANCE: The prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains poor after surgery. ...
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Yang H, et al. J Clin Oncol. 2018 Sep 20;36(27):2796-2803. doi: 10.1200/JCO.2018.79.1483. Epub 2018 Aug 8. J Clin Oncol. 2018. PMID: 30089078 Free PMC article. Clinical Trial.
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. Ando N, et al. Ann Surg Oncol. 2012 Jan;19(1):68-74. doi: 10.1245/s10434-011-2049-9. Epub 2011 Aug 31. Ann Surg Oncol. 2012. PMID: 21879261 Clinical Trial.
METHODS: Eligible patients with clinical stage II or III, excluding T4, squamous cell carcinoma were randomized to undergo surgery followed (group 1) or preceded (group 2) by chemotherapy consisting of two courses of cisplatin plus 5-fluorouracil. The primary end point was …
METHODS: Eligible patients with clinical stage II or III, excluding T4, squamous cell carcinoma were randomized to undergo surgery followed …
Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma.
Luo HC, Wu JJ, Zhu LJ, Cai LJ, Feng J, Shen ZY, Wu MJ, Chen FF, Fu ZC, Xie FW. Luo HC, et al. Medicine (Baltimore). 2023 Aug 25;102(34):e34647. doi: 10.1097/MD.0000000000034647. Medicine (Baltimore). 2023. PMID: 37653737 Free PMC article.
What is more, Cox risk regression model has also been used to evaluate the risk factors affecting the prognosis of LAESCC. The cases of a total of 5328 newly diagnosed patients with esophageal cancer were collected, and a total of 363 patients were included in the study, w …
What is more, Cox risk regression model has also been used to evaluate the risk factors affecting the prognosis of LAESCC. The cases …
Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma.
Qiu J, Lin H, Ke D, Yu Y, Xu J, Qiu H, Zheng Q, Li H, Zheng H, Liu L, Wang Z, Yao Q, Li J. Qiu J, et al. Front Immunol. 2023 May 8;14:1066255. doi: 10.3389/fimmu.2023.1066255. eCollection 2023. Front Immunol. 2023. PMID: 37223094 Free PMC article.
BACKGROUND: To explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (RIL) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). ...In addition, we identified body mass index (BMI), tumor …
BACKGROUND: To explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (R …
Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Tsuchiya N, Kunisaki C, Sato S, Tanaka Y, Sato K, Watanabe J, Takeda K, Kosaka T, Akiyama H, Endo I. Tsuchiya N, et al. Langenbecks Arch Surg. 2022 Aug;407(5):1911-1921. doi: 10.1007/s00423-022-02445-4. Epub 2022 Mar 1. Langenbecks Arch Surg. 2022. PMID: 35230525
The median overall survival (OS) was 15.2 months, and the 3-year survival rate was 32.1%. High Glasgow prognostic score (GPS) and advanced N-category independently predicted the objective response to CRT. ...CONCLUSIONS: High GPS and advanced N-category predicted …
The median overall survival (OS) was 15.2 months, and the 3-year survival rate was 32.1%. High Glasgow prognostic score (GPS) and adv …
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn MJ, Sun JM. Park S, et al. Cancer. 2022 Jun 1;128(11):2148-2158. doi: 10.1002/cncr.34176. Epub 2022 Mar 23. Cancer. 2022. PMID: 35319779 Free article.
CONCLUSIONS: Durvalumab and tremelimumab with definitive CCRT had promising efficacy in patients with locally advanced ESCC. In addition, PD-L1 expression had strong predictive value in the study population....
CONCLUSIONS: Durvalumab and tremelimumab with definitive CCRT had promising efficacy in patients with locally advanced ESCC. In addition, PD …
Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs.
Tseng I, Ai D, Chen Y, Zhu H, Li F, Xu Y, Yu L, Liu Q, Deng J, Hao S, Zhu Z, Zhao W, Fan M, Li L, Su F, Zhao K. Tseng I, et al. Radiat Oncol. 2023 Oct 19;18(1):172. doi: 10.1186/s13014-023-02354-w. Radiat Oncol. 2023. PMID: 37858121 Free PMC article.
Logistic analysis identified BM V5 (OR 4.24 and 2.29) as an independent predictor of inadequate lymphocyte recovery from G4 or G1-3 ALC nadir, respectively. CONCLUSIONS: Insufficient lymphocyte recovery might serve as a valuable prognostic factor, regardless of whet …
Logistic analysis identified BM V5 (OR 4.24 and 2.29) as an independent predictor of inadequate lymphocyte recovery from G4 or G1-3 A …
Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, Zhao J, Er P, Zhang T, Chen X, Wang Y, Jiang Y, Wang Q, Zhang B, Qian D, Wang J, Zhou D, Ren X, Yu Z, Zhao L, Yuan Z, Wang P, Pang Q. Zhang W, et al. Oncologist. 2021 Jul;26(7):e1110-e1124. doi: 10.1002/onco.13797. Epub 2021 Jun 5. Oncologist. 2021. PMID: 33893689 Free PMC article. Clinical Trial.
Further studies combining chemoradiotherapy with immunotherapy in locally advanced ESCC and exploration of predictive biomarkers are warranted. BACKGROUND: We conducted a phase Ib study of radiotherapy plus programmed cell death protein 1 (PD-1) monoclonal antibody camreli …
Further studies combining chemoradiotherapy with immunotherapy in locally advanced ESCC and exploration of predictive biomarkers are …
202 results